Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Challenges in managing myeloma patients

Meletios Dimopoulos • 2 Jun 2020
EHA 2020
Multiple Myeloma

Meletios Dimopoulos, MD, of the Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses some of the challenges facing the management of myeloma patients and highlights the need for novel therapies to myeloma subgroups that have an unmet need. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meletios Dimopoulos

Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma 1:19
Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma
Meletios Dimopoulos • 7 Dec 2025
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM 0:51
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM
Meletios Dimopoulos • 7 Dec 2025
Long-term follow-up of belantamab mafodotin plus pomalidomide and dexamethasone in myeloma: DREAMM-8 1:07
Long-term follow-up of belantamab mafodotin plus pomalidomide and dexamethasone in myeloma: DREAMM-8
Meletios Dimopoulos • 7 Dec 2025
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma 2:08
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma
Meletios Dimopoulos • 12 Jun 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals